Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study

Table 3 Ratio of C _min and C _max values to Historical Population Means by antiretroviral drug and dose

			C_min			C_max
Antiretroviral agent		n	n (%) >1.5 historical pop Mean	Media ratio to historical population mean median ratio (IQR)	p-value ^a	n (%) >1.5 Historical pop mean	Media ratio to historical population mean Median ratio ( IQR)	p-value ^a
All		82	28 (34.1%)	1.21 (0.72-1.89)	<.01	7 (8.5%)	0.82 (0.59-1.14)	<.01
Atazanavir	400 QD	9	2 (22.2%)	0.78 (0.35-1.37)	0.71	0 (0.0%)	0.59 (0.31-0.94)	0.04
Atazanavir (boosted with ritonavir)	300 QD	18	4 (22.2%)	0.97 (0.77-1.42)	0.58	0 (0.0%)	0.66 (0.51-0.85)	<.001
All Atazanavir		27	6 (22.2%)	0.95 (0.53-1.42)	0.76	0 (0.0%)	0.65 (0.44-0.87)	<.0001
Lopinavir (boosted with ritonavir)	400 BID	16	3 (18.8%)	1.21 (0.79-1.40)	0.27	0 (0.0%)	0.86 (0.74-1.18)	0.32
Lopinavir (boosted with ritonavir)	800 QD	4	3 (75.0%)	3.79 (1.44-4.86)	0.25	0 (0.0%)	0.99 (0.63-1.26)	0.63
All Lopinavir		20	6 (30.0%)	1.22 (0.79-1.81)	0.11	0 (0.0%)	0.86 (0.72-1.21)	0.29
Efavirenz	600 DQ	16	6 (37.5%)	0.95 (0.67-1.95)	0.37	4 (25.0%)	0.79 (0.57-1.27)	0.63
Nevirapine	200 BID	11	5 (45.5%)	1.41 (0.91-1.93)	0.03	2 (18.2%)	0.96 (0.84-1.37)	0.46
Nevirapine	400 QD	8	5 (62.5%)	2.08 (0.90-2.53)	0.08	1 (12.5%)	0.96 (0.72-1.40)	0.95
All Nevirapine		19	10 (52.6%)	1.62 (0.91-2.32)	<0.01	3 (15.8%)	0.96 (0.81-1.37)	0.47

IQR, Interquartile range. ^a Sign rank test for a median ratio different than 1.

ISSN: 1471-2334